A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

December 16, 2022

Study Completion Date

May 12, 2023

Conditions

Cold UrticariaCold Contact UrticariaSymptomatic DermographismSymptomatic DermatographismCholinergic Urticaria

Interventions

DRUG

CDX-0159

Administered intravenously

Trial Locations (1)

Charite University, Berlin